ED Toxicology
[ED Toxicology ]
EPTIS Ringversuch Nr. 142475 | Letze Änderung 2024-05-22 | URL: https://www.eptis.bam.de/pts142475 https://www.eptis.bam.de/pts142475
| Name des Anbieters | ||||||||||||||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||
| Sprache(n) | ||||||||||||||||||||||
| Anmerkungen | ED Toxicology is available as part of a comprehensive suite of programmes for the Clinical Laboratory to cover all of its basic core tests. These include: Serum Chemistry, Urine Chemistry, ED Toxicology, Lipids, Bilirubin and Serum Indices. Four human serum and whole blood samples are distributed monthly, with a minimum of 48 samples distributed over the year covering a wide range including samples at the clinically important decision points. The samples consist of a panel of 8 linearly related samples where salicylate, paracetamol and ethanol have been added gravimetrically to “off the clot” serum from healthy volunteers tested negative for these analytes. The linear panel are distributed on a number of occasions over that period which are used to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Separate samples are available for serum Ethylene glycol and Methanol and for Whole Blood Ethanol. Key Features: - Toxic pathological range covered, cut-off levels where clinical decisions can have serious consequences for the patient. - Liquid human serum samples. Linearly related panel covering the analytical and Toxic pathological range. - Samples assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. - Challenging samples at clinically relevant cut-off concentrations. For more information: https://www.weqas.com/services/eqa/ed-toxicology/ or contact@weqas.com | |||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||
|
||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||
| Zielgruppe des Ringversuchs | Laboratory Diagnostic services and Point of Care Testing services | |||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | |||||||||||||||||||||
| Weitere Ziele | validation of testing methods | |||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 nicht für alle Parameter |
|||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||
| Teilnahmegebühr | Fee dependent on number of participating sections and proximetry of testing methods | |||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 4 x 1.0mL Whole Blood Ethanol 4 x 0.5mL. ) | |||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 1968 | |||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.